Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for Today: MSFT, BLK, NOC

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), BlackRock (BLK), and Northrop Grumman (NOC).

    TherapeuticsMD Falls on Likely Delay in TX-004HR Approval

    Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July

      Arpita Dutt headshot

      Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

      Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

        The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

        The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics

          Vertex Pharmaceuticals (VRTX) Shares March Higher, Can It Continue?

          As of late, it has definitely been a great time to be an investor in Vertex Pharmaceuticals Incorporated (VRTX).

            Arpita Dutt headshot

            3 of the Best & Worst Performing Drug Stocks of Q1

            Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.

              Amgen Files for Xgeva Label Expansion, To Include Myeloma

              Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.

                Arpita Dutt headshot

                Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug

                Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.

                  5 Stocks that Outperformed the S&P 500 in Q1

                  First quarter was quite impressive and we have selected five top-ranked stocks that surpassed the S&P 500 index during the period.

                    5 Stocks that Chaperoned Nasdaq to Double-Digit Gains in Q1

                    The tech-heavy index, Nasdaq, outperformed and recorded a gain of 10% in the first quarter.

                      Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk

                      A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control

                        AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval

                        AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.

                          AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

                          AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

                            Mark Vickery headshot

                            Top Research Reports for Today: DIS, TXN, LMT

                            Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Texas Instruments (TXN), and Lockheed Martin (LMT).

                              Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III

                              Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

                                Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

                                  5 Toxic Stocks to Dump or Play Short to Make Gains

                                  Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

                                    Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

                                      Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M

                                      Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

                                        Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

                                          Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte

                                          Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte

                                            5 Toxic Stocks to Abandon or Play Short Right Now

                                            In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.

                                              Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                                              Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                                                Sweta Killa headshot

                                                Biotech ETFs Powered by Q4 Earnings

                                                Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

                                                  5 Toxic Stocks to Dump or Play Short for Gains

                                                  Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.